Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageTandem Diabetes Care is a global leader in insulin delivery and diabetes technology, specializing in the design, development, and commercialization of advanced solutions that reduce the burden of diabetes management. We serve nearly 500,000 people living with diabetes in more than 25 countries worldwide. Our strategy is to offer flexibility and choice in intelligent insulin delivery systems through an accessible portfolio of market-leading pumps, applications and insights.
In the company’s own words · 10-K filed Feb 19, 2026 · SEC EDGAR
Business segments
Q1 2026 · $247.2MThe company’s own SEC segment disclosure.
- Supplies And Other$136.8M55%
- Pump$110.4M45%
Tandem Diabetes Care, Inc. (TNDM) reported revenue of $247M in Q1 2026 (quarter ended March 31, 2026), up 5.5% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $20M. For the full year FY2025, revenue was $1.01B (+7.9% year on year) and net income −$205M. Its largest product in 2026-Q1 was Supplies And Other at $137M, 55% of the disclosed total, just ahead of Pump at 45%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.